Skip to main content
Erschienen in: Breast Cancer 2/2008

01.04.2008 | Case Report

Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors

verfasst von: Daisuke Takabatake, Naruto Taira, Kenjiro Aogi, Shozo Ohsumi, Shigemitsu Takashima, Takeshi Inoue, Rieko Nishimura

Erschienen in: Breast Cancer | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

We report two cases of occult breast cancer in which masses were completely nonpalpable and positron emission tomography-computed tomography (PET-CT) was extremely helpful in identifying the primary tumor. Case 1 involved a 56-year-old woman with enlarged lymph nodes 3 cm in size in the axilla. Based on excisional biopsy, axillary lymph node metastasis of breast cancer was suspected but an obvious primary tumor in the breast was not identifiable on mammography, contrast-enhanced CT, or ultrasonography. Faint accumulation of fluorodeoxyglucose (FDG) was noted only on PET-CT, so the site was considered to be the primary site, and operation was performed. As a result of postoperative pathological examination, ductal carcinoma in-situ (DCIS) was diagnosed. Case 2 involved a 55-year-old woman with enlarged lymph nodes 3 cm in size in the axilla. Based on the excisional biopsy, axillary lymph node metastasis of breast cancer was suspected. In this case as well, an obvious primary tumor was not identifiable with palpation or mammography. On PET-CT, faint accumulation of FDG was noted in the vicinity of the CD regions, or upper and lower outer quadrants. When contrast-enhanced CT and ultrasonography were performed, a faint nodular opacity less than 1 cm in size corresponding to this site was found and diagnosed as the primary site, operation was subsequently performed. Pathologic diagnosis indicated invasive cancer. PET-CT is a helpful option for the diagnosis of occult breast cancer with primary sites that conventional imaging studies have difficulty identifying.
Literatur
1.
Zurück zum Zitat Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.PubMed Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.PubMed
2.
Zurück zum Zitat Dockerty MB, Gray HK, Pierce EH. Surgical significance of isolated axillary adenopathy. Ann Surg. 1957;145(1):104–7.PubMedCrossRef Dockerty MB, Gray HK, Pierce EH. Surgical significance of isolated axillary adenopathy. Ann Surg. 1957;145(1):104–7.PubMedCrossRef
3.
Zurück zum Zitat Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.PubMedCrossRef Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.PubMedCrossRef
4.
Zurück zum Zitat Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205(2):437–40.PubMed Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205(2):437–40.PubMed
5.
Zurück zum Zitat Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology. 1997;202(2): 413–20.PubMed Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology. 1997;202(2): 413–20.PubMed
6.
Zurück zum Zitat Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat. 1997;44(2):179–82.PubMedCrossRef Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat. 1997;44(2):179–82.PubMedCrossRef
7.
Zurück zum Zitat Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.PubMedCrossRef Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.PubMedCrossRef
8.
Zurück zum Zitat Akashi-Tanaka S, Fukutomi T, Miyakawa K, Uchiyama N, Nanasawa T, Tsuda H. Contrast-enhanced computed tomography detection of occult breast cancers presenting as axillary masses. Breast Cancer Res Treat. 1999;55(1):97–101.PubMedCrossRef Akashi-Tanaka S, Fukutomi T, Miyakawa K, Uchiyama N, Nanasawa T, Tsuda H. Contrast-enhanced computed tomography detection of occult breast cancers presenting as axillary masses. Breast Cancer Res Treat. 1999;55(1):97–101.PubMedCrossRef
9.
Zurück zum Zitat Block EF, Meyer MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surg. 1998;64(9):906–8.PubMed Block EF, Meyer MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surg. 1998;64(9):906–8.PubMed
10.
Zurück zum Zitat Scoggins CR, Vitola JV, Sandler MP, Atkinson JB, Frexes-Steed M. Occult breast carcinoma presenting as an axillary mass. Am Surg. 1999;65(1):1–5.PubMed Scoggins CR, Vitola JV, Sandler MP, Atkinson JB, Frexes-Steed M. Occult breast carcinoma presenting as an axillary mass. Am Surg. 1999;65(1):1–5.PubMed
11.
Zurück zum Zitat van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 2002;236(5):619–24.PubMedCrossRef van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 2002;236(5):619–24.PubMedCrossRef
12.
Zurück zum Zitat Avril N, Rose CA, Scelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Scwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and Limitation. J Clin Oncol. 2000;18:3495–502.PubMed Avril N, Rose CA, Scelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Scwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and Limitation. J Clin Oncol. 2000;18:3495–502.PubMed
13.
Zurück zum Zitat Owaki T, Kijima Y, Yoshinaka H, Uenosono Y, Yoshioka T, Natsugoe S, Aikou T. Ductal carcinoma in-situ of the breast detected by [F-18] fluorodeoxyglucose positron emission tomography. Breast Cancer. 2006;13:210–3.PubMedCrossRef Owaki T, Kijima Y, Yoshinaka H, Uenosono Y, Yoshioka T, Natsugoe S, Aikou T. Ductal carcinoma in-situ of the breast detected by [F-18] fluorodeoxyglucose positron emission tomography. Breast Cancer. 2006;13:210–3.PubMedCrossRef
14.
Zurück zum Zitat Walter C, Scheidhauer K, Scharl A, Goering UJ, Theissen P, Kugel H, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol. 2003;13:1651–6.PubMedCrossRef Walter C, Scheidhauer K, Scharl A, Goering UJ, Theissen P, Kugel H, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol. 2003;13:1651–6.PubMedCrossRef
Metadaten
Titel
Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors
verfasst von
Daisuke Takabatake
Naruto Taira
Kenjiro Aogi
Shozo Ohsumi
Shigemitsu Takashima
Takeshi Inoue
Rieko Nishimura
Publikationsdatum
01.04.2008
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2008
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-007-0027-7

Weitere Artikel der Ausgabe 2/2008

Breast Cancer 2/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.